---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-001386"
form_type: "8-K"
ticker: "MD"
cik: "0000893949"
company_name: "Pediatrix Medical Group, Inc."
filed_at: "2022-02-17T23:59:59+00:00"
generated_at: "2026-06-27T07:16:08.433537+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mednax Q4 EPS $0.47 ($0.52 adj); revenue $499M; FY22 EBITDA guidance at least $270M

## Summary
- GAAP EPS from continuing ops $0.47 versus $0.05 in Q4 2020; adjusted EPS $0.52 versus $0.25.
- Revenue $498.5M (+20% YoY), driven by 17.6% same-unit growth (volume +6.3%, reimbursement +11.3%).
- Adjusted EBITDA $81M in Q4 ($58.3M prior year); full-year 2021 $265.5M.
- Preliminary 2022 adjusted EBITDA guidance at least $270M, excluding CARES Act funds.
- Post-quarter refinancing: issued $400M 5.375% notes due 2030, new $450M revolver, $250M term loan; total debt $750M.

## SEC filing metadata
- accession: 0000950170-22-001386
- form_type: 8-K
- ticker: MD
- cik: 0000893949
- company_name: Pediatrix Medical Group, Inc.
- filed_at: 2022-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/893949/000095017022001386/0000950170-22-001386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/893949/000095017022001386/md-20220217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-001386
- JSON: https://secwatch.observer/filing/0000950170-22-001386.json
- Plain text: https://secwatch.observer/filing/0000950170-22-001386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.